Toronto, Ontario, Apr 30, 2021 (Newsfile Corp via COMTEX) -- Toronto, Ontario--(Newsfile Corp. - April 30, 2021) - Datametrex AI Limited (otcqb:DTMXF) /zigman2/quotes/201317471/delayed DE:D4G -9.92% (the "Company" or "Datametrex") is pleased to report that it has filed on SEDAR its consolidated financial statements and related management discussion and analysis for its year-end financial results for the year 2020.
In 2020, the Company recorded record revenue of $12,378,02, a 264% increase from 2019, and significantly improved its cash balance, up 1,648% from 2019. Adjusted EBITDA also improved significantly ($862,494) in 2020 compared to ($2,126,155) in 2019. This Adjusted EBITDA reflects the Company's operations, not including non-cash items. The Company's AI and Tech revenue also increased to $4,101,967 from $3,369,069 despite the pandemic situation.
The following is selected financial information for the twelve months ending December 31, 2020, along with comparative results. Please refer to the 2020 Filing in its entirety, which is available under Datametrex's profile at www.sedar.com .
"The Company has made significant progress in strengthening its balance sheet and positioning Datametrex for incredible market growth anticipated by shifting health policy and regulation," says Marshall Gunter, CEO of Datametrex. "We have entered 2021 coming off a record year in revenue of $12,378,024 with most of the revenue in Q3 and Q4 related to new COVID business, providing the Company enough capital to invest and focus on increasing its revenue pipeline while continuing to promote the opportunities in both AI and the healthcare sector and leveraging the fantastic businesses that have been added to Datametrex over the last two quarters."
Financial Highlights for the Fiscal Year ending December 31, 2020:
Revenue of $12,378,024 compared to revenue of $3,400,835 for FY 2019;
Cash balance of $1,971,987 compared to a cash balance of $119,675 for FY 2019;
All figures are in Canadian dollars unless otherwise noted:
||FY 2020||FY 2019||% Change|
|COVID-19 Test kits revenue||$8,276,057||$0||100%|
|AI and Technology revenue||$4,101,967||$3,369,069||22%|
|Income/Loss before income taxes||($4,403,976)||($3,191,710)||238%|
|Income per share - basic||(0.020)||(0.012)||66%|
The following reconciles the net income EBITA and Adjusted EBITA (non IFRS):
||FY 2020||FY 2019|
||December 31, 2020||December 31, 2019|
|Add: interest and accretion||$47,489||$94,837|
|Add: income tax provisions (recovery)||$602,300||($277,750)|
|Add: depreciation & amortization||$751,099||$821,747|
|EDITDA (non IFRS)||($3,605,388)||($2,144,229)|
|Add: share based compensation||$2,742,894||$18,074|
|Adjusted EDITDA (non IFRS)||($862,494)||($2,126,155)|
||FY 2020||FY 2019||Dollar Change||Percent Change|
Fiscal 2020 Highlights and Subsequent Events
The Company's revenue increased by 264% in 2020 compared to 2019 bringing in over $12M in revenue.
The Company sold over 23,700 onsite tests for the film industry at locations in Montreal, Toronto and Vancouver for the months of October through December 2020.
The Company started testing services in Q4 to 6 production companies in Toronto and 11 production companies in Vancouver, administering approximately 6,000 tests per week.
The Company has received $1.8 million from the exercise of share purchase warrants and options.